Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours

被引:23
作者
McNally, VA
Patterson, AV
Williams, KJ
Cowen, RL
Stratford, IJ
Jaffar, M
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland 1000, New Zealand
基金
英国医学研究理事会;
关键词
hypoxia; bioreductive prodrugs; indolequinone; GDEPT; P450; reductase; angiogenesis; VEGF; nitric oxide synthase (NOS); angiogenic inhibitors; gene delivery;
D O I
10.2174/1381612023394548
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quinone based bioreductive drugs have, potentially, a very versatile use in cancer chemotherapy. They can be activated by DT-diaphorase and hence can be used to target tumour types rich in this O-2-independent reductase enzyme. Small molecular modifications can substantially reduce specificity for DT-diaphorase and under these circumstances the quinones become much less toxic in air but retain their potent cytotoxic effects under hypoxic conditions. Our understanding of the reductive (bio) chemistry of indolequinones, in particular, has subsequently allowed us to develop a platform technology where almost any therapeutic entity can potentially be delivered, selectively, to hypoxic tumours. Antiangiogenic approaches are currently receiving a substantial amount of attention and this review brings their development into context in view of the hypoxia dependence for neovascularization. Lastly, the use of bioreductive drugs when combined with hypoxia-mediated gene therapy is described. Such an approach provides a unique dual level of specificity for targeting hypoxic tumours and potentially can provide substantial therapeutic benefit.
引用
收藏
页码:1319 / 1333
页数:15
相关论文
共 161 条
[1]  
ADAMS GE, 1980, J NATL CANCER I, V64, P555
[2]   Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis [J].
Albina, JE ;
Reichner, JS .
CANCER AND METASTASIS REVIEWS, 1998, 17 (01) :39-53
[3]  
Arima J, 2000, CANCER, V88, P1131
[4]   TUMOR VASCULATURE - A POTENTIAL THERAPEUTIC TARGET [J].
BAILLIE, CT ;
WINSLET, MC ;
BRADLEY, NJ .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :257-267
[5]   7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase [J].
Balzarini, J ;
Gamboa, AE ;
Esnouf, R ;
Liekens, S ;
Neyts, J ;
De Clercq, E ;
Camarasa, MJ ;
Pérez-Pérez, MJ .
FEBS LETTERS, 1998, 438 (1-2) :91-95
[6]   Indolequinone antitumor agents:: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity [J].
Beall, HD ;
Winski, S ;
Swann, E ;
Hudnott, AR ;
Cotterill, AS ;
O'Sullivan, N ;
Green, SJ ;
Bien, R ;
Siegel, D ;
Ross, D ;
Moody, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (24) :4755-4766
[7]   An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer [J].
Binley, K ;
Iqball, S ;
Kingsman, A ;
Kingsman, S ;
Naylor, S .
GENE THERAPY, 1999, 6 (10) :1721-1727
[8]  
Birner P, 2000, CANCER RES, V60, P4693
[9]   Characterization of physiologically regulated vectors for the treatment of ischemic disease [J].
Boast, K ;
Binley, K ;
Iqball, S ;
Price, T ;
Spearman, H ;
Kingsman, S ;
Kingsman, A ;
Naylor, S .
HUMAN GENE THERAPY, 1999, 10 (13) :2197-2208
[10]   Tumor angiogenesis - new drugs on the block [J].
Brower, V .
NATURE BIOTECHNOLOGY, 1999, 17 (10) :963-968